These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1686184)

  • 21. Medication compliance and substance abuse among schizophrenic patients.
    Pristach CA; Smith CM
    Hosp Community Psychiatry; 1990 Dec; 41(12):1345-8. PubMed ID: 1980483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
    Day JC; Bentall RP; Roberts C; Randall F; Rogers A; Cattell D; Healy D; Rae P; Power C
    Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of treatment resistant schizophrenia unresponsive to clozapine.
    Barnes TR; McEvedy CJ; Nelson HE
    Br J Psychiatry Suppl; 1996 Dec; (31):31-40. PubMed ID: 8968653
    [No Abstract]   [Full Text] [Related]  

  • 24. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
    Stanković Z; Britvić D; Vuković O; Ille T
    Psychiatr Danub; 2008 Mar; 20(1):42-52. PubMed ID: 18376330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discontinuation of neuroleptic medication in older, outpatient schizophrenics. A placebo-controlled, double-blind trial.
    Ruskin PE; Nyman G
    J Nerv Ment Dis; 1991 Apr; 179(4):212-4. PubMed ID: 1672547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Compliance problems in treatment of schizophrenic patients].
    Barnas C; Hummer M; Fleischhacker WW
    Wien Med Wochenschr; 1998; 148(11-12):281-3. PubMed ID: 9746971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term psychiatric patients' knowledge about their medication.
    Tempier R
    Psychiatr Serv; 1996 Dec; 47(12):1385-7. PubMed ID: 9117480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose antipsychotic medication.
    Bennie EH
    Br J Psychiatry; 1994 Oct; 165(4):553. PubMed ID: 7528625
    [No Abstract]   [Full Text] [Related]  

  • 30. A prototype approach toward antipsychotic medication adherence in schizophrenia.
    Freudenreich O; Tranulis C
    Harv Rev Psychiatry; 2009; 17(1):35-40. PubMed ID: 19205965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Issues in drug administration in a psychiatric rehabilitation unit.
    Trauer T; Vaddadi K; Soosai E
    Int J Soc Psychiatry; 1995; 41(3):174-9. PubMed ID: 8847198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orally disintegrating antipsychotics may promote compliance and adherence in patients with schizophrenia.
    Tornatore FL
    J Clin Psychiatry; 2005 Nov; 66(11):1493-4; author reply 1494. PubMed ID: 16420093
    [No Abstract]   [Full Text] [Related]  

  • 33. Antipsychotic medication adherence: is there a difference between typical and atypical agents?
    Dolder CR; Lacro JP; Dunn LB; Jeste DV
    Am J Psychiatry; 2002 Jan; 159(1):103-8. PubMed ID: 11772697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study of the clinical utility of radioreceptor assay in outpatients with schizophrenia receiving high doses of neuroleptics.
    Gagné MA; Cormier H; Leblanc G; Lévesque D; Di Paolo T
    Can J Psychiatry; 1993 Oct; 38(8):534-40. PubMed ID: 7902199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review.
    Valenstein M; Ganoczy D; McCarthy JF; Myra Kim H; Lee TA; Blow FC
    J Clin Psychiatry; 2006 Oct; 67(10):1542-50. PubMed ID: 17107245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Factors related to treatment adherence in schizophrenic patients].
    García Cabeza I; Sánchez Díaz EI; Sanz Amador M; Gutiérrez Rodríguez M; González de Chávez M
    Actas Esp Psiquiatr; 1999; 27(4):211-6. PubMed ID: 10469940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurement.
    Herron AJ; Mariani JJ; Pavlicova M; Parrinello CM; Bold KW; Levin FR; Nunes EV; Sullivan MA; Raby WN; Bisaga A
    Drug Alcohol Depend; 2013 Feb; 128(1-2):77-82. PubMed ID: 22921475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years.
    Linden M; Godemann F; Gaebel W; Köpke W; Müller P; Müller-Spahn F; Pietzcker A; Tegeler J
    Schizophr Bull; 2001; 27(4):585-96. PubMed ID: 11824485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virtual reality assessment of medication compliance in patients with schizophrenia.
    Baker EK; Kurtz MM; Astur RS
    Cyberpsychol Behav; 2006 Apr; 9(2):224-9. PubMed ID: 16640484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancing medication use in schizophrenic patients.
    Diamond RJ
    J Clin Psychiatry; 1983 Jun; 44(6 Pt 2):7-14. PubMed ID: 6133855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.